Epinephrine is a Small Molecule owned by Viatris, and is involved in 3 clinical trials, which were completed.

Epinephrine acts directly on alpha-adrenergic receptors and to a lesser degree, beta-adrenergic receptors. Through direct action on alpha1-adrenergic receptors in the mucosa of the respiratory tract, it produces vasoconstriction. It relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors.

The revenue for Epinephrine is expected to reach a total of $5.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Epinephrine NPV Report.

Epinephrine is currently owned by Viatris.

Epinephrine Overview

Epinephrine (Epipen/ Fastjekt/ Altellus/ Adrenaline/ Epipen E Z Pen/ Epi E Z Pen JR/ Epipen Jr/ Glaucon) is a sympathomimetic hormone from the adrenal medulla. It is formulated as solution for intramuscular or subcutaneous route of administration and drops solution for ophthalmic route of administration. Epinephrine is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects as order hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects as triatoma, mosquitoes, allergen immunotherapy, foods, drugs, diagnostic testing substances as radiocontrast media and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.

Viatris Overview

Viatris is a healthcare company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceuticals in multiple forms for various disease conditions related to respiratory, cardiovascular, central nervous system (CNS) system and allergy, skin disease, and cancer. It also offers anti-retrovirals, anaphylaxis products, and active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries. Viatris is headquartered in Canonsburg, Pennsylvania, the US.

The company reported revenues of (US Dollars) US$17,886.3 million for the fiscal year ended December 2021 (FY2021), an increase of 49.7% over FY2020. The operating loss of the company was US$42 million in FY2021, compared to an operating loss of US$227.6 million in FY2020. The net loss of the company was US$1,269.1 million in FY2021, compared to a net loss of US$669.9 million in FY2020. The company reported revenues of US$4,078.2 million for the third quarter ended September 2022, a decrease of 0.9% over the previous quarter.

Quick View – Epinephrine

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Epinephrine
Administration Pathway
  • Intramuscular
  • Ophthalmic
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Immunology
  • Ophthalmology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.